Welcome to our dedicated page for Enlivex news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex stock.
Enlivex Therapeutics Ltd. (ENLV) generates news at the intersection of clinical-stage immunotherapy and digital asset treasury management. Company announcements highlight progress in the development of Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state, and its application in moderate-to-severe knee osteoarthritis. Press releases have detailed positive three- and six-month topline data from the ENX-CL-05-001 Phase I/II trial, including clinically meaningful and statistically significant reductions in pain and improvements in function in age-related primary knee osteoarthritis patients.
Investors following ENLV news will also see updates on Enlivex’s adoption of a digital asset treasury strategy centered on the RAIN token. The company reports that RAIN is the primary asset of its digital asset treasury and describes RAIN as the governance and utility token of a fully decentralized predictions and options protocol built on the Arbitrum network. News items have covered a large private placement intended to fund RAIN token accumulation, an exclusive option agreement to purchase RAIN tokens, and the listing of RAIN on major cryptocurrency exchanges such as KuCoin.
Additional ENLV coverage includes SEC-related disclosures, board and governance changes, shareholder communications, and participation in scientific conferences and investor events. Readers can expect articles on clinical data presentations, new patents related to Allocetra™ in osteoarthritis, shareholder letters outlining strategic roadmaps, and virtual webinars or fireside chats with company leadership and external experts. For those tracking both biotechnology developments in knee osteoarthritis and corporate activity around a RAIN-focused digital asset treasury, the Enlivex news feed provides a consolidated view of the company’s key milestones and strategic decisions.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced the dosing of the first two patients in a Phase II clinical trial of Allocetra for severe and critical COVID-19 patients. This multi-center study aims to recruit up to twenty-four patients to evaluate Allocetra alongside standard care, focusing on safety, tolerability, and efficacy. The trial follows a successful Phase Ib trial where all five patients recovered. No severe adverse events were reported. The trial will observe patients for 28 days post-administration.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced that the Israeli Ministry of Health has authorized a Phase II clinical trial for AllocetraTM targeting severe and critical COVID-19 patients. The trial aims to evaluate safety and efficacy, recruiting up to 24 patients. This follows positive results from a Phase Ib trial where all five treated patients recovered. Further details will be submitted to expedite regulatory review. The Phase Ib trial showed no severe adverse events, indicating a favorable safety profile for AllocetraTM.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced positive outcomes from a clinical trial of its therapy AllocetraTM on COVID-19 patients in severe/critical condition. In the trial, five patients experienced complete recovery and were discharged from the hospital after an average of 5.5 days (severe) and 8.5 days (critical). No severe adverse events were reported. Following these promising results, Enlivex plans to transition to a larger Phase II trial for COVID-19 patients, contingent upon regulatory approval. AllocetraTM could fill a treatment gap for severe COVID-19 cases.
Enlivex Therapeutics Ltd. has received a notice of allowance for a new patent in China concerning its immunotherapy product candidate, ALLOCETRA. This patent is expected to provide enhanced intellectual property protection, covering methods, uses, and pharmaceutical compositions. The patent is anticipated to be issued in Q4 2020. ALLOCETRA aims to address unmet medical needs related to organ dysfunction and acute multiple organ failure due to conditions such as Sepsis and COVID-19, in addition to treating solid tumors through immunotherapy mechanisms.
Enlivex Therapeutics (Nasdaq: ENLV) announced the publication of compelling preclinical data demonstrating a 90% reduction in mortality using its AllocetraTM treatment in a murine model of severe sepsis. The study highlights AllocetraTM's effectiveness in resolving organ failure and cytokine storms, showing significant results in a clinically relevant cecal ligation and puncture (CLP) model. This data complements previous Phase Ib clinical trial outcomes, supporting AllocetraTM's potential application in treating severe sepsis and COVID-19-related complications.
Enlivex Therapeutics announced that the Japan Patent Office has allowed a patent application for ALLOCETRA, their immunotherapy candidate. The patent will provide intellectual property protection for its use and pharmaceutical compositions. The company anticipates the patent to be issued in Q3 2020. ALLOCETRA is designed to target serious clinical indications, including organ dysfunction related to sepsis and COVID-19, as well as modulating the tumor microenvironment for solid tumors. Enlivex focuses on developing allogeneic drugs for immune system rebalancing.
Enlivex Therapeutics (Nasdaq: ENLV) will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 8:00 AM ET.
A live webcast of the presentation can be accessed here.
Enlivex specializes in developing immunotherapy solutions aimed at rebalancing the immune system for severe conditions without approved treatments, including Cytokine Release Syndrome and solid tumors.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has initiated a multi-center Phase II clinical trial for Allocetra in COVID-19 patients, following promising results in a prior Phase Ib trial for sepsis. The trial aims to assess the safety and efficacy of Allocetra in addressing cytokine storms and organ dysfunction associated with severe COVID-19 symptoms. Up to five patients will be recruited per center, with primary endpoints including changes in PaO2/FiO2 ratio and adverse events. The study runs independently of an upcoming Phase IIb trial for sepsis planned for late 2020.